Recon: Pharma industry laments Senate drug pricing bill; GSK, Mersana sign $1.4B preclinical ADC deal

• ‘Litany of false promises’: Pharma bemoans drug pricing bill as patient advocates celebrate (Fierce) (Generics Bulletin)
• Haggling With Pharma: Medicare Drug Price Negotiations Explained (Bloomberg)
• With drug pricing almost done, Congress looks to wrap up FDA user fee legislation (Endpoints)
• The GOP blocked an insulin price cap: What it means for diabetics (Washington Post)
• After addressing FDA’s concerns, Reata’s wait for ataxia drug decision extended by 3 months (Fierce) (Endpoints)
• FDA's vaccine adcomm to review first fecal transplant to treat C. difficile infections (Endpoints)
• Verona’s shares jump as COPD drug hits goal in phase 3, teeing up FDA filing (Fierce)
• FDA slaps CorMedix with a second manufacturing-related drug rejection (Fierce) (Endpoints)
• US Moves to Stretch Out Monkeypox Vaccine Supply (NYT) (Washington Post)
• Will low-dose vaccination stretch the monkeypox vaccine supply, or backfire? (STAT)
• US to buy Siga's IV drug worth $26 million to fight monkeypox outbreak (Reuters)
• US to stop supplying Lilly's mAb for Covid-19 this month as commercial market awaits (Endpoints)
• America has a maternal mortality crisis. Biden push aims to change that (Washington Post)

• EU regulator begins review of Pfizer-BioNTech's variant-adapted COVID shot (Reuters)
• COVID-19 vaccines: Commission and Moderna adapt delivery schedules for late summer and winter (European Commission)
• Anger and anxiety stalk EU’s monkeypox vaccine lottery (Politico)
• Advanz bags EU rights to Polypid’s prolonged-release antibiotic (Fierce)
• Agency donates breathing devices for premature babies to Ukraine (Reuters)
• Pfizer manufacturing workers walk out after similar pay disputes at GSK, Novo Nordisk (Fierce)
• Mixed Results For China’s First Home-Grown COVID Antiviral (Scrip)
• New Graft Probes Cast Shadow Over China's Drug Pricing, Reimbursement Systems (Pink Sheet)

• GSK Ups Ante in ADC Discovery Game with $1.4B Mersana Option Deal (Biospace) (Endpoints) (Pharmalive)
• Merck is back in Alzheimer’s saddle with $1B+ Cerevance pact, years after dropping the BACE (Fierce)
• Biopharma Industry Shows Signs of Life in Ever-Changing Economic Landscape (Biospace)
• Kodiak manages to score a win for its Eylea rival — but the major test is still ahead (Endpoints)
• BeiGene and Novartis Make Late-Stage Progress against Liver Cancer (Biospace)
• AstraZeneca ADC barrels forward as Keytruda combo data make case for lung cancer use (Fierce)
• Verona, Daiichi Sankyo, AstraZeneca and Kodiak Score Big Wins in Key Diseases  (Biospace)
• Aptar takes up option on Orbital high dose dry powder inhaler in pursuit of halcyon drug delivery days (Fierce)
• For the second time, Pfizer tries a warranty in response to concerns over high drug costs (STAT)
• Struggling Novavax halves its sales forecast as COVID shot launch sputters (Fierce) (Endpoints)
• Teva bullish ahead of 2-step biosimilar attack on Abbvie’s blockbuster Humira (Biopharma Reporter)
• Q&A: Astellas' retiring head of development reflects on gene therapy deaths (Endpoints)
• Why non-opioid pain drugs keep failing — and what's next for the field (Endpoints)

• Phillips In Talks With DOJ Over Breathing Machine Recalls (MedTech Insight)
• Call for EU reference laboratories sent to Member States (EC)
• The rise of SkyWalker: FDA clears surgical robot for orthopedic procedures (Fierce)
• Hyris T-Cell Test Gains CE-IVD Mark (FDAnews)
• FDA’s hearing-aid guidance clears regulatory review amid push by lawmakers for retail sales approval (MedTech Dive)
• BD begins tender offers for up to $500M in debt to advance repayment strategy (Medtech Dive)

• Eight Indicted In Alleged Genetic Testing Fraud (MedTech Insight)
• Medtronic Settles Man’s Suit Over Alleged Pacemaker Defect (Bloomberg)
• Viatris Must Face Novo Nordisk Ozempic Patent Claims in Delaware (Bloomberg)
• Karyopharm’a Win Over Investors on Cancer Drug Data Affirmed (Bloomberg)